A 2026 Nature study by the Rasmussen Group examines GLP-1 receptor activation and aging in mice, offering vital insights for active adults on GLP-1 therapies.
In August 2026, the International Center for Molecular Medicine at the University of Copenhagen announced a compelling new study published in Nature by the Rasmussen Group. The research detailed how late-life treatment with semaglutide improved physiological function and extended lifespan in female mice. For active adults who leverage GLP-1 based medications, this research provides mechanistic reassurance that these agents actively reshape appetite and metabolic pathways. Maintaining an active lifestyle requires careful attention to physical capability as we age. This study reinforces the profound need to align protein intake, micronutrient balance, and resistance training with ongoing weight loss.
The study specifically examined 20-month-old female C57BL/6 mice. The Nature news report described this age as roughly comparable to 60-year-old humans. These animals received semaglutide for three months, and researchers continued the treatment to assess lifespan impacts. The research was motivated by the established effects of GLP-1 receptor activation on food intake, type 2 diabetes, and obesity.
According to the University of Copenhagen, the semaglutide treatment improved physiological function and attenuated several hallmarks of aging. The treated mice achieved a median lifespan of 834 days, which compared favorably with 742 days in the control group. This outcome represents a median lifespan that was approximately 12% longer in the semaglutide group. The researchers also noted that the treatment modulated nutrient sensors and conserved genetic regulators involved in aging.
The semaglutide-treated mice naturally reduced their calorie intake by approximately 24%. To separate the effects of reduced food intake from drug-specific benefits, the researchers included an untreated group whose calorie intake was matched to the semaglutide animals. The calorie-restricted comparison group showed similar longevity outcomes to the semaglutide group. However, the semaglutide-treated mice performed better in several tests, including a spatial-memory experiment.
The University of Copenhagen reported more favorable semaglutide trajectories for exploratory drive, spatial memory, and glucose control compared to calorie restriction. These results suggest that at least some effects of semaglutide were not explained solely by eating fewer calories. While researchers did not establish the precise mechanism responsible for those additional effects, the data provides a strong foundation for future study. The University of Copenhagen characterized semaglutide as functioning in this specific model as a calorie-restriction mimetic.
The scientific community views these findings as a significant step forward in metabolic research. Michael Corley, an aging scientist at the University of California San Diego, told Nature that GLP-1 medicines have been "on the top of everyone's list as the most exciting candidates" for longevity research. Corley described the work as "a very rigorous animal study that showed a positive signal." He emphasized that the findings remain preliminary, noting that proving whether GLP-1 drugs can be prescribed specifically for longevity could take years.
University of California Berkeley biologist and co-author of the study Danica Chen shared her perspective on the mechanisms at play. She said it was natural to ask whether GLP-1 medicines might act as calorie-restriction mimetics since they consistently reduce food cravings and calorie intake. Chen noted that the stronger performance of semaglutide-treated mice in some experiments was "really a surprise" to the research team. She interpreted the result as suggesting additional benefits not explained by calorie reduction, even though the core driver remains unclear.
For active adults who value worldly travel and demanding sports, the most relevant near-term issue is understanding how substantial appetite suppression affects daily physical capability. Navigating high altitudes on a ski trip or recovering from a long hike requires precise fueling. When appetite is chemically reduced, prioritizing high-quality nutrition becomes essential for maintaining the strength necessary for physical independence. A 2026 review noted that protein recommendations for people using incretin-based therapies are largely extrapolated from broader weight-loss and sarcopenia research.
The practical challenge during GLP-1 assisted weight loss often shifts from controlling food intake to making a limited appetite work nutritionally. The 2026 review generally proposed 1.2-1.6 grams of protein per kilogram of body weight per day during active weight loss. Older adults, people at risk of sarcopenia, and highly active individuals may have higher requirements. These individuals could potentially need up to 1.6-2.0 grams per kilogram per day to support tissue recovery.
Distributing protein strategically throughout your day is highly recommended when managing a busy travel itinerary. The same review proposed an approximate per-meal target of 0.3-0.4 grams per kilogram of adjusted body weight. It also recommended approximately 2.5-3.0 grams of leucine per meal for many adults. Hitting these marks can aid in preserving muscle and performance during the GLP-1 transition.
Resistance training is commonly recommended alongside weight-loss treatment because it supports skeletal-muscle mass, physical function, and bone-health outcomes. Weight loss from incretin-based therapy can include reductions in fat-free mass. The review reported that approximately 20-50% of weight lost in analyses of incretin-based therapies could consist of lean body mass. The clinical significance of these changes is not fully established, as fat-free mass includes more than just skeletal muscle.
While no clinical studies have directly tested a resistance-training program specifically during incretin-based therapy, broader athletic research provides clear guidance. The review recommended progressing toward at least 150 minutes per week of moderate-to-vigorous activity. It also advised incorporating at least two days per week of whole-body resistance training. A practical program for travelers could focus on two weekly full-body sessions.
These workouts should prioritize foundational movements like squats, hinges, and pushes. Incorporating pulls and loaded carries will also ensure you remain physically prepared for strenuous activities. Evaluating longevity protocols against foundational health strategies consistently points to strength training as an irreplaceable priority.
Reduced energy intake and potential gastrointestinal symptoms can make it difficult for some GLP-1 users to meet nutritional needs, particularly while traveling. The 2026 review advised emphasizing minimally processed, nutrient-dense foods rather than assuming that a supplement is automatically required. Focusing on quality whole foods ensures you receive the necessary vitamins and minerals to support sustained energy. Reviewing a comprehensive guide to metabolic health after 40 can help you construct a resilient dietary framework.
Nutrient-dense options like seafood, eggs, and dairy are incredibly useful. Legumes, tofu, and lean meats also provide excellent dietary foundations. Incorporating vegetables, whole grains, nuts, and seeds is equally important. Fiber should be increased gradually and paired with adequate hydration, which is especially important for people experiencing constipation.
Claims about micronutrient deficiencies should be handled cautiously, as routine blanket supplementation is not justified without proper biochemical screening.
Adapting to altitude or enduring long flights can sometimes mask the early signs of nutritional shortfalls. Persistent nausea, unusual fatigue, declining exercise performance, or unintended weakness should always prompt a discussion with a prescribing clinician. The review specifically highlighted gastrointestinal side effects, dehydration, nutrient deficiencies, and lean-mass loss as issues requiring attention.
The Rasmussen Group findings provide a compelling biological reason to study GLP-1 receptor activation beyond simple glucose control. However, they do not yet demonstrate that semaglutide is a human longevity treatment. The most defensible objective for an active adult is prioritizing functional capability to ensure years of continued adventure.
Active adults leveraging GLP-1 therapies must proactively prioritize adequate protein intake and structured resistance training to preserve the functional capability required for demanding travel and lifelong sport.
Stay connected for research and practical guidance on longevity, strength, recovery, energy and active living. New ideas to help you stay capable, curious and ready for more.
Explore practical guidance on strength, recovery, energy, travel and longevity for a life that stays active.
explore the Blog
